About the Company
inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
14
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $INMB News
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its ...
Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a ...
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: INMB) (the “Company”), a clinical ...
Assembly Bio to launch four infectious disease trials in 2024
Assembly Bio has four candidates in its pipeline, one of which is being developed as part of a partnership with Gilead ...
Graphite Bio declares special $1.03 dividend
Graphite Bio (GRPH) declares $1.03/share special dividend. Payable March 21; for shareholders of record March 18; ex-div March 15. See GRPH Dividend Scorecard, ...
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
Allogene Therapeutics ALLO announced that it has entered into a non-exclusive licensing agreement with privately-held Arbor ...
Merus, Gilead ink $1.5B+ deal; Biomx merges with Adaptive Phage
Though down nearly 6% in January, the BioWorld Drug Developers Index (BDDI) rebounded in February, finishing the month with a 4.41% increase and outperforming both the Nasdaq Biotechnology Index (NBI; ...
INmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro
Patients with Alzheimer's Disease show improvement in brainwaves following 4 weeks of XPro therapy. Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: ...
Loading the latest forecasts...